We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+18.81%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.59B
AUM Growth
+$289M
Cap. Flow
+$97.5M
Cap. Flow %
3.76%
Top 10 Hldgs %
46.26%
Holding
80
New
11
Increased
26
Reduced
24
Closed
16

Top Buys

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$75.7M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$51.8M
3
XNCR icon
Xencor
XNCR
+$48.5M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$48.4M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$39.6M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$89.8M
2
AZN icon
AstraZeneca
AZN
+$70.2M
3
CELG
Celgene Corp
CELG
+$68.1M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$61.8M
5
CTLT
CATALENT, INC.
CTLT
+$34.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.32%
2 Financials 0.74%
3 Communication Services 0.37%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UHS icon
51
Universal Health Services
UHS
$9.43B
$7.99M 0.31%
67,500
-149,600
-69% -$17.8M
ONC
52
BeOne Medicines Ltd
ONC
$33.8B
$6.72M 0.26%
+40,000
New +$5.42M
PETQ
53
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$5.24M 0.2%
197,159
-27,184
-12% -$636K
ATYR
54
aTyr Pharma
ATYR
$46.4M
$5M 0.19%
134,642
-129
-0.1% -$6.05K
ACRS icon
55
Aclaris Therapeutics
ACRS
$730M
$1.87M 0.07%
106,820
-200
-0.2% -$4.24K
OVID icon
56
Ovid Therapeutics
OVID
$435M
$1.14M 0.04%
160,718
-152,064
-49% -$1.23M
IHF icon
57
iShares US Healthcare Providers ETF
IHF
$1.18B
$330K 0.01%
+10,435
New +$339K
EXAS
58
DELISTED
Exact Sciences
EXAS
$328K 0.01%
+8,130
New +$397K
HZNP
59
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$284K 0.01%
20,000
– –
FLXN
60
DELISTED
Flexion Therapeutics, Inc.
FLXN
$223K 0.01%
+9,930
New +$242K
ARAY icon
61
Accuray
ARAY
$28.4M
$145K 0.01%
+29,000
New +$152K
ADVM
62
DELISTED
Adverum Biotechnologies
ADVM
$129K 0.01%
2,224
– –
ALGN icon
63
Align Technology
ALGN
$12B
– –
-1,140
Closed -$253K
AZN icon
64
AstraZeneca
AZN
$263B
– –
-1,010,800
Closed -$70.2M
BMRN icon
65
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-2,500
Closed -$223K
GMED icon
66
Globus Medical
GMED
$10.4B
– –
-208,600
Closed -$8.57M
HUM icon
67
Humana
HUM
$46.7B
– –
-1,000
Closed -$248K
NKTR icon
68
Nektar Therapeutics
NKTR
$2.39B
– –
-355
Closed -$318K
PCRX icon
69
Pacira BioSciences
PCRX
$1.02B
– –
-5,190
Closed -$237K
PRQR icon
70
ProQR Therapeutics
PRQR
$243M
– –
-1,558,392
Closed -$5.03M
CTLT
71
DELISTED
CATALENT, INC.
CTLT
– –
-833,063
Closed -$34.2M
ASXC
72
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-385,984
Closed -$9.68M
SGEN
73
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-1,156,021
Closed -$61.8M
CLVS
74
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-1,320,027
Closed -$89.8M
VCRA
75
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
– –
-7,000
Closed -$212K
1 2
3
4

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q1 2018 Portfolio in Review

As of Q1 2018, Redmile Group held 80 positions worth $2.59B, up 13% from $2.3B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group deployed $97.5M of net new capital in Q1 2018, opening 11 new positions and adding to 26 existing holdings. Its largest new stake was AveXis, Inc. Common Stock: 636,900 shares worth $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $30.3M trimmed.

  • Redmile Group's largest Q1 2018 buy was AveXis, Inc. Common Stock: 636,900 shares worth $78.7M.
  • Redmile Group added most to Atara Biotherapeutics in Q1 2018, an estimated $51.8M increase.
  • Redmile Group's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $30.3M.
  • Redmile Group fully exited Clovis Oncology, Inc. in Q1 2018, selling an estimated $89.8M.
  • Redmile Group's ten largest holdings make up 46% of its $2.59B portfolio in Q1 2018.
  • Redmile Group opened 11 new positions and closed 16 in Q1 2018.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.59B.

Based on Redmile Group's 13F filing for Q1 2018, filed 15 May 2018.